{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:24:01Z","timestamp":1791275041518,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,6,11]],"date-time":"2012-06-11T00:00:00Z","timestamp":1339372800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tyrosine kinase inhibitors (TKIs) are currently approved for the treatment of metastatic renal cell carcinoma (mRCC). The cardiotoxic effects of sorafenib and sunitinib may cause hypertension, left ventricular ejection fraction (LVEF) dysfunction and\/or congestive heart failure (CHF), and arterial thrombo-embolic events (ATE). Only three cases of coronary artery disease related to sorafenib therapy have been described in the literature, and all were due to arterial vasospasm without evidence of coronary artery stenosis on angiography. Cardiotoxicity is commonly associated with the presence of cardiovascular risk factors, such as a history of hypertension or coronary artery disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>We describe a patient who experienced an unusual cardiac event after 2\u2009years of sorafenib treatment. A 58-year-old man with mRCC developed acute coronary syndrome (ischemia\/infarction) associated with critical sub-occlusion of the common trunk of the left coronary artery and some of its branches, which was documented on coronary angiography. The patient underwent triple coronary artery bypass surgery, and sorafenib treatment was discontinued. He did not have any cardiovascular risk factors, and his cardiac function and morphology were normal prior to sorafenib treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Further investigation of a larger patient population is needed to better understand cardiac damage due to TKI treatment. Understanding the usefulness of careful cardiovascular monitoring might be important for the prevention of fatal cardiovascular events, and to avoid discontinuation of therapy for the underlying cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-12-231","type":"journal-article","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T17:24:38Z","timestamp":1354728278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib"],"prefix":"10.1186","volume":"12","author":[{"given":"Maria Abbondanza","family":"Pantaleo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mandrioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maristella","family":"Saponara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Nannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Erente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Biasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,11]]},"reference":[{"key":"3193_CR1","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, Kidney Cancer, http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/kidney.pdf. V. 2.2010"},{"issue":"2","key":"3193_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1634\/theoncologist.2011-S2-45","volume":"16","author":"AM Molina","year":"2011","unstructured":"Molina AM, Motzer RJ: Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist. 2011, 16 (2): 45-50. 10.1634\/theoncologist.2011-S2-45.","journal-title":"Oncologist"},{"issue":"1","key":"3193_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6004\/jnccn.2011.0124","volume":"9","author":"GR Hudes","year":"2011","unstructured":"Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson MD, Motzer RJ, Pili R, Roethke S, Srinivas S: NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw. 2011, 9 (1): 1-29.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"3193_CR4","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/cncr.24864","volume":"116","author":"WM Stadler","year":"2010","unstructured":"Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH: Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM; ARCCS Study Investigators: Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010, 116 (5): 1272-1280. 10.1002\/cncr.24864.","journal-title":"Cancer"},{"issue":"2","key":"3193_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R: Bukowski RM; TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007, 356 (2): 125-134. 10.1056\/NEJMoa060655.","journal-title":"N Engl J Med"},{"issue":"3","key":"3193_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/02841860903524396","volume":"49","author":"V Ranpura","year":"2010","unstructured":"Ranpura V, Hapani S, Chuang J, Wu S: Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010, 49 (3): 287-297. 10.3109\/02841860903524396.","journal-title":"Acta Oncol"},{"key":"3193_CR7","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1200\/JCO.2010.34.4309","volume":"29","author":"CJ Richards","year":"2011","unstructured":"Richards CJ, Je Y, Schutz FAB, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK: Incidence and Risk of Congestive Heart Failure in Patients With Renal and Nonrenal Cell Carcinoma Treated With Sunitinib. J Clin Oncol. 2011, 29: 3450-3456. 10.1200\/JCO.2010.34.4309.","journal-title":"J Clin Oncol"},{"issue":"13","key":"3193_CR8","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","volume":"28","author":"TK Choueiri","year":"2010","unstructured":"Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J: Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010, 28 (13): 2280-2285. 10.1200\/JCO.2009.27.2757.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3193_CR9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s00059-011-3444-5","volume":"36","author":"T Naib","year":"2011","unstructured":"Naib T, Steingart RM, Chen CL: Sorafenib-associated multivessel coronary artery vasospasm. Herz. 2011, 36 (4): 348-351. 10.1007\/s00059-011-3444-5.","journal-title":"Herz"},{"issue":"3","key":"3193_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jjcc.2009.03.009","volume":"54","author":"Y Arima","year":"2009","unstructured":"Arima Y, Oshima S, Noda K, Fukushima H, Taniguchi I, Nakamura S, Shono M, Ogawa H: Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol. 2009, 54 (3): 512-515. 10.1016\/j.jjcc.2009.03.009.","journal-title":"J Cardiol"},{"issue":"8","key":"3193_CR11","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/nrclinonc.2010.67","volume":"7","author":"I Porto","year":"2010","unstructured":"Porto I, Leo A, Miele L, Pompili M, Landolfi R, Crea F: A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol. 2010, 7 (8): 476-480. 10.1038\/nrclinonc.2010.67.","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"3193_CR12","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64 (19): 7099-7109. 10.1158\/0008-5472.CAN-04-1443.","journal-title":"Cancer Res"},{"issue":"20","key":"3193_CR13","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009, 27 (20): 3312-3318. 10.1200\/JCO.2008.19.5511.","journal-title":"J Clin Oncol"},{"key":"3193_CR14","first-page":"23","volume":"23","author":"C Porta","year":"2011","unstructured":"Porta C, Procopio G, Carten\u00ec G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E: Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. 2011, 23: 23-","journal-title":"BJU Int"},{"key":"3193_CR15","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007, 370: 2011-2019. 10.1016\/S0140-6736(07)61865-0.","journal-title":"Lancet"},{"issue":"9","key":"3193_CR16","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdn168","volume":"19","author":"ML Telli","year":"2008","unstructured":"Telli ML, Witteles RM, Fisher GA, Srinivas S: Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008, 19 (9): 1613-1618. 10.1093\/annonc\/mdn168.","journal-title":"Ann Oncol"},{"issue":"9","key":"3193_CR17","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","volume":"20","author":"G Di Lorenzo","year":"2009","unstructured":"Di Lorenzo G, Autorino R, Bruni G, Carten\u00ec G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M, Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido S: Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009, 20 (9): 1535-1542. 10.1093\/annonc\/mdp025.","journal-title":"Ann Oncol"},{"issue":"32","key":"3193_CR18","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","volume":"26","author":"M Schmidinger","year":"2008","unstructured":"Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008, 26 (32): 5204-5212. 10.1200\/JCO.2007.15.6331.","journal-title":"J Clin Oncol"},{"key":"3193_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrd3252","volume":"10","author":"T Force","year":"2011","unstructured":"Force T, Kolaja KL: Cardiotoxicity of kinase inhibitors: the prediction and traslantion of preclinical models to clinical outcomes. Nat Rev Cancer. 2011, 10: 111-126. 10.1038\/nrd3252.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3193_CR20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrc2106","volume":"7","author":"T Force","year":"2007","unstructured":"Force T, Krause DS, Van Etten RA: Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007, 7 (5): 332-344. 10.1038\/nrc2106.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"3193_CR21","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1172\/JCI200420317","volume":"114","author":"O Yamaguchi","year":"2004","unstructured":"Yamaguchi O, Watanabe T, Nishida K, Kashiwase K, Higuchi Y, Takeda T, Hikoso S, Hirotani S, Asahi M, Taniike M, Nakai A, Tsujimoto I, Matsumura Y, Miyazaki J, Chien KR, Matsuzawa A, Sadamitsu C, Ichijo H, Baccarini M, Hori M, Otsu K: Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest. 2004, 114 (7): 937-943.","journal-title":"J Clin Invest"},{"issue":"12","key":"3193_CR22","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald DM: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007, 96 (12): 1788-1795. 10.1038\/sj.bjc.6603813.","journal-title":"Br J Cancer"},{"issue":"4","key":"3193_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1159\/000321175","volume":"85","author":"TJ Lim","year":"2010","unstructured":"Lim TJ, Lee JH, Chang SG, Lee CH, Min GE, Yoo KH, Jeon SH: Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate. Urol Int. 2010, 85 (4): 475-478. 10.1159\/000321175.","journal-title":"Urol Int"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-12-231\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:28:33Z","timestamp":1630614513000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,11]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["3193"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-12-231","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,11]]},"assertion":[{"value":"11 January 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"231"}}